We are live on ! Find out more
TCM

Tamarack Capital Management Portfolio holdings

AUM $840M
1-Year Est. Return 19.47%
This Fund
S&P 500
This Quarter Est. Return
-1.85%
1 Year Est. Return
+19.47%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$451M
AUM Growth
-$38.8M
Cap. Flow
-$25.2M
Cap. Flow %
-5.59%
Top 10 Hldgs %
66.12%
Holding
39
New
10
Increased
13
Reduced
5
Closed
9

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$23.5M
2
ELGX
Endologix Inc
ELGX
+$12.9M
3
BIO icon
Bio-Rad Laboratories Class A
BIO
+$7.94M
4
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$7.23M
5
PDCO
Patterson Companies, Inc.
PDCO
+$5.79M

Top Sells

Rank Stock Value
1
VOLC
VOLCANO CORPORATION COM STK
VOLC
+$21.1M
2
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$20.5M
3
CFN
CAREFUSION CORPORATION
CFN
+$16.9M
4
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$13M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$11.7M

Sector Composition

Rank Sector Weight
1 Healthcare 56.27%
2 Technology 1.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$98.5M 21.84%
+500,000
New +$98.8M
ELGX
2
DELISTED
Endologix Inc
ELGX
$35M 7.75%
330,000
+92,500
+39% +$12.9M
SPNC
3
DELISTED
Spectranetics Corp
SPNC
$30.6M 6.77%
1,150,000
– –
MDT icon
4
Medtronic
MDT
$107B
$22.9M 5.08%
+370,000
New +$23.5M
CFN
5
DELISTED
CAREFUSION CORPORATION
CFN
$22.6M 5.02%
500,000
-375,000
-43% -$16.9M
ITGR icon
6
Integer Holdings
ITGR
$3.35B
$20.2M 4.48%
520,779
+114,999
+28% +$4.92M
AUXL
7
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$19.4M 4.3%
650,000
-293,526
-31% -$6.22M
ALKS icon
8
Alkermes
ALKS
$8.82B
$19.3M 4.28%
450,000
-75,000
-14% -$3.36M
PDCO
9
DELISTED
Patterson Companies, Inc.
PDCO
$15.3M 3.4%
370,000
+145,000
+64% +$5.79M
NXTM
10
DELISTED
NxStage Medical Inc.
NXTM
$14.4M 3.2%
1,100,000
+50,000
+5% +$673K
MDXG icon
11
MiMedx Group
MDXG
$626M
$14.3M 3.16%
2,000,000
+225,000
+13% +$1.57M
PM icon
12
PUT
Philip Morris
PM
$301B
$12.5M 2.77%
+150,000
New +$12.7M
TEVA icon
13
Teva Pharmaceuticals
TEVA
$35.9B
$12.4M 2.74%
230,000
-16,500
-7% -$874K
PFE icon
14
CALL
Pfizer
PFE
$140B
$11.8M 2.62%
+421,600
New +$11.8M
LMNX
15
DELISTED
Luminex Corp
LMNX
$10.7M 2.38%
550,000
+50,000
+10% +$914K
SRGA
16
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$10.5M 2.33%
73,333
+1,666
+2% +$242K
ATRC icon
17
AtriCure
ATRC
$1.77B
$10.3M 2.28%
700,000
+113,445
+19% +$1.81M
BIO icon
18
Bio-Rad Laboratories Class A
BIO
$8.42B
$9.46M 2.1%
83,378
+67,009
+409% +$7.94M
NTUS
19
DELISTED
Natus Medical Inc
NTUS
$8.11M 1.8%
274,695
+121,162
+79% +$3.34M
CBST
20
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$7.3M 1.62%
+110,000
New +$7.23M
INGN icon
21
Inogen
INGN
$167M
$5.37M 1.19%
+260,617
New +$5.29M
VOLC
22
DELISTED
VOLCANO CORPORATION COM STK
VOLC
$5.32M 1.18%
500,000
-1,518,300
-75% -$21.1M
STRM
23
DELISTED
Streamline Health Solutions
STRM
$5.27M 1.17%
75,867
+7,534
+11% +$528K
ICUI icon
24
ICU Medical
ICUI
$3.93B
$5.14M 1.14%
+80,125
New +$4.91M
IMPR
25
DELISTED
IMPRIVATA, INC COM
IMPR
$4.66M 1.03%
300,000
+104,447
+53% +$1.54M
1
2

Similar funds

RI
Relational Investors San Diego, California $840M AUM 0.57% 1-Year Est. Return
CWA
Constellation Wealth Advisors New York $903M AUM 2.38% 1-Year Est. Return
GHF
Good Harbor Financial Barrington, Illinois $916M AUM 5.96% 1-Year Est. Return
F
FutureAdvisor San Francisco, California $617M AUM 6.57% 1-Year Est. Return
TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
BMCMI
Bryn Mawr Capital Management Inc Bryn Mawr, Pennsylvania $577M AUM 6.5% 1-Year Est. Return
GACM
Green Arrow Capital Management New York $535M AUM 14.21% 1-Year Est. Return
AH
Achievement Holdings Chicago, Illinois $1.2B AUM 9.2% 1-Year Est. Return

Tamarack Capital Management's Q3 2014 Portfolio in Review

As of Q3 2014, Tamarack Capital Management held 39 positions worth $451M, down 7.9% from $490M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Tamarack Capital Management withdrew a net $25.2M in Q3 2014, closing 9 positions and reducing 5 holdings. Its most notable exit was COVIDIEN PLC COM SHS NEW (IRELAND), an estimated $20.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 50% a quarter earlier, followed by Technology.

Against the trend, Tamarack Capital Management opened a new position in Medtronic worth $22.9M.

  • Tamarack Capital Management's largest Q3 2014 buy was Medtronic: 370,000 shares worth $22.9M.
  • Tamarack Capital Management added most to Endologix Inc in Q3 2014, an estimated $12.9M increase.
  • Tamarack Capital Management's biggest Q3 2014 reduction was VOLCANO CORPORATION COM STK, cutting an estimated $21.1M.
  • Tamarack Capital Management fully exited COVIDIEN PLC COM SHS NEW (IRELAND) in Q3 2014, selling an estimated $20.5M.
  • Tamarack Capital Management's ten largest holdings make up 66% of its $451M portfolio in Q3 2014.
  • Tamarack Capital Management opened 10 new positions and closed 9 in Q3 2014.
  • Tamarack Capital Management's portfolio value fell 7.9% quarter-over-quarter to $451M.

Based on Tamarack Capital Management's 13F filing for Q3 2014, filed 7 Nov 2014.